enGene Therapeutics
ENGN
11 hedge funds and large institutions have $131M invested in enGene Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
61.15% more ownership
Funds ownership: 0% → 61.15% (+61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$19.9M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$10.9M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$10M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.01M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.03M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIS
1
FCPM III Services
Naarden,
Netherlands
| $80.1M | +$76.8M | +8,677,951 | New |
|
|
BI
2
BVF Inc
San Francisco,
California
| $20.8M | +$19.9M | +2,251,037 | New |
|
|
BOCH
3
Blue Owl Capital Holdings
New York
| $11.4M | +$10.9M | +1,234,760 | New |
|
|
OFM
4
Omega Fund Management
Boston,
Massachusetts
| $10.4M | +$10M | +1,131,175 | New |
|
|
VC
5
Vivo Capital
Palo Alto,
California
| $6.26M | +$6.01M | +678,705 | New |
|
|
PAMP
6
Polar Asset Management Partners
Toronto,
Ontario, Canada
| $1.07M | +$1.03M | +116,942 | New |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $349K | +$335K | +37,845 | New |
|
8
Goldman Sachs
New York
| $346K | +$331K | +37,447 | New |
|
9
Citadel Advisors
Miami,
Florida
| $185K | +$177K | +20,057 | New |
|
10
UBS Group
Zurich,
Switzerland
| $17.9K | +$17.1K | +1,937 | New |
|
11
Morgan Stanley
New York
| $148 | +$142 | +16 | New |
|
ENGN Hedge Fund Activity: Q4 2023 in Review
11 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q4 2023, worth a combined $131M.
Buyers outnumbered sellers: 11 funds opened new ENGN positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $19.9M.
- 11 institutional investors held enGene Therapeutics (ENGN) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $131M of enGene Therapeutics stock for Q4 2023.
- 11 funds opened new enGene Therapeutics positions in Q4 2023 and 0 closed out, a net change of +11 holders.
- The largest enGene Therapeutics buyer in Q4 2023 was BVF Inc, an estimated $19.9M added.
Based on aggregated 13F filings for Q4 2023.